New Delhi: Following the encouraging results of the trials of coronavirus vaccine being developed by AstraZeneca and Oxford University, Adar Poonawalla, Chief Executive Officer of Serum Institute of India (SII) has said at least 300 million doses of the potential vaccine will be ready by December.
He told national media India Today on Tuesday that 300-400 million doses of the potential vaccine ‘Covishield’ will be ready by December.
Adar Poonawalla also said that the vaccine will cost around Rs 1,000 in India.
“The trials have shown promising results and we are extremely happy about it. We will be applying for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India. In addition, we will soon start manufacturing the vaccine in large volumes,” he said.
The interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed that the vaccine was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants, AstraZeneca said in a statement.